{
    "clinical_study": {
        "@rank": "163120", 
        "acronym": "Diast Dysfkt", 
        "arm_group": [
            {
                "arm_group_label": "Linagliptin", 
                "arm_group_type": "Active Comparator", 
                "description": "Linagliptin 5 mg (tablets) once daily for 6 month"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo (tablets) once daily for 6 month"
            }
        ], 
        "brief_summary": {
            "textblock": "Examination of the effect of Linagliptin versus placebo on diastolic function in patients\n      with type 2 diabetes mellitus and diastolic dysfunction as assessed by transthoracic\n      echocardiography.\n\n      Furthermore the effect on serum levels of NT-pro BNP as a biomarker of heart failure will be\n      investigated."
        }, 
        "brief_title": "Diastolic Dysfunction", 
        "completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Diabetes Mellitus Type 2 (T2DM),", 
            "Left Ventricular Diastolic Dysfunction"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "detailed_description": {
            "textblock": "Treatment:\n\n      The Patients will receive Linagliptin 5 mg QD or placebo for a period of 6 months.\n\n      The echocardiography and 24h RR measurement will be performed at baseline and 6 months after\n      initiation of the therapy.\n\n      The blood chemistry (Glucose, HbA1c, BNP) will be evaluated at baseline as well as 3 and 6\n      months after initiation of the therapy."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Diabetes mellitus Type 2\n\n          2. Age > 50 years\n\n          3. HbA1c > 7%\n\n          4. Left ventricular diastolic dysfunction determined by echocardiography as average E/\u00e9\n             \u226513 or average E/\u00e9\u22658 and LA volume \u226534ml/m2\n\n          5. Stable anti-diabetic medication for the last 6 weeks  which should include a maximal\n             tolerated dose of metformin (unless contraindication or intolerance to metformin does\n             exist).\n\n          6. Indication to increase anti-diabetic medication as judged by the investigator\n\n          7. Written informed consent prior to study participation\n\n        Exclusion Criteria:\n\n          1. Diabetes mellitus type 1\n\n          2. Echocardiography:\n\n               -  decreased left ventricular systolic function, ejection fraction (EF) <45%\n\n               -  regional wall motion abnormalities\n\n               -  hypertrophic cardiomyopathy (septum >15mm)\n\n               -  severe valvular dysfunction\n\n          3. Uncontrolled hypertension\n\n          4. Atrial fibrillation\n\n          5. Obstructive sleep apnea syndrome\n\n          6. Use of DPP-4 Inhibitor (Dipeptidyl-peptidase IV Inhibitor), GLP 1 agonists,\n             Thiazolindinedione\n\n          7. Kidney disease CKD 4 and more (GFR < 30 ml/min/1.73)\n\n          8. Liver disease (ALT or AST > 3 times the upper limit of norm) or known liver cirrhosis\n\n          9. Active malignant disease\n\n         10. HbA1c > 8.5%\n\n         11. Recent (<3 months) clinically significant coronary or cerebral vascular event\n\n         12. Pregnant females as determined by positive [serum or urine] hCG test at Screening or\n             prior to dosing. Participants of child-bearing age should use adequate contraception\n             as defined in the study protocol.\n\n         13. Lactating females\n\n         14. The subject has a history of any other illness, which, in the opinion of the\n             Investigator, might pose an unacceptable risk by administering study medication.\n\n         15. The subject received an investigational drug within 30 days prior to inclusion into\n             this study\n\n         16. The subject has any current or past medical condition and/or required medication to\n             treat a condition that could affect the evaluation of the study\n\n         17. The subject is unwilling or unable to follow the procedures outlined in the protocol\n\n         18. The subject is mentally or legally incapacitated"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "50 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 20, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01888796", 
            "org_study_id": "12-025", 
            "secondary_id": [
                "2012-003858-81", 
                "EK 113/13"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Linagliptin", 
                "intervention_name": "Linagliptin", 
                "intervention_type": "Drug", 
                "other_name": "Trade name Trajenta\u00ae by Boehringer Ingelheim (BI) Pharma GmbH & Co KG, Biberach, Germany"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "BI 1356"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "T2DM", 
            "diastolic dysfunction"
        ], 
        "lastchanged_date": "October 28, 2013", 
        "location": {
            "contact": {
                "email": "nmarx@ukaachen.de", 
                "last_name": "Nikolaus Marx, Univ.-Prof.", 
                "phone": "+49 241 80 89301"
            }, 
            "contact_backup": {
                "email": "asudhoff@ukaachen.de", 
                "last_name": "Angela Sudhoff, M.Sc.", 
                "phone": "+49 241 80 37429"
            }, 
            "facility": {
                "address": {
                    "city": "Aachen", 
                    "country": "Germany", 
                    "zip": "52074"
                }, 
                "name": "Department of Internal Medicine I, University Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effect of Linagliptin Therapy on Myocardial Diastolic Function in Patients With Type 2 Diabetes Mellitus", 
        "overall_contact": {
            "email": "nmarx@ukaachen.de", 
            "last_name": "Nikolaus Marx, Univ.-Prof.", 
            "phone": "+49 241 80 89301"
        }, 
        "overall_contact_backup": {
            "email": "mlehrke@ukaachen.de", 
            "last_name": "Michael Lehrke, PD Dr. med.", 
            "phone": "+49 241 8089301"
        }, 
        "overall_official": {
            "affiliation": "Department of Internal Medicine I, RWTH Aachen University Hospital", 
            "last_name": "Nikolaus Marx, Univ.-Prof.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Change in left ventricular diastolic function between baseline and after 6 month as determined by 2D and novel 3D parameter global Strain Rate E Change in left ventricular diastolic function between baseline and after 6 month as determined by standardized parameter E/\u00e9 and left atrial (LA) volume", 
            "measure": "Change in left ventricular diastolic function", 
            "safety_issue": "No", 
            "time_frame": "baseline and 6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01888796"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Change in serum NT-pro BNP levels", 
            "measure": "Change in serum NT-pro BNP levels", 
            "safety_issue": "No", 
            "time_frame": "baseline and 6 months"
        }, 
        "source": "RWTH Aachen University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "RWTH Aachen University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}